摘要
Until recently,anti-platelet/coagulation therapy had not been recommended for patients with cirrhosis.Although venous thrombosis is one of the representative complications of cirrhosis and ischemic disorders associated with atherosclerosis are not infrequent in cirrhotic patients,many clinicians have tended to hesitate to introduce anti-platelet/coagulation therapy to their patients.Undoubtedly,this is due to the increased risk of hemorrhagic diathesis in cirrhotic patients.However,accumulating evidence has revealed the benefits of anti-platelet/coagulation therapy for cirrhotic patients.In addition to the safety of the therapy carried out against cardiovascular diseases in cirrhotic patients,some clinical data have indicated its preventive effect on venous thrombosis.Moreover,the efficacy of antiplatelet/coagulation therapy against cirrhosis itself has been demonstrated both clinically and experimentally.The conceptual basis for application of anti-platelet/coagulation therapy against cirrhosis was constructed through two pathologic studies on intrahepatic thrombosis in cirrhotic livers.It may be better to use thrombopoietinreceptor agonists,which have been tested as a treatment for cirrhosis-related thrombocytopenia,in combination with anti-platelet drugs to reduce the risk of venous thrombosis.During the last decade,the World Journal of Gastroenterology,a sister journal of World Journal of Hepatology,has been one of the main platforms of active discussion of this theme.
Until recently, anti-platelet/coagulation therapy hadnot been recommended for patients with cirrhosis.Although venous thrombosis is one of the representativecomplications of cirrhosis and ischemic disordersassociated with atherosclerosis are not infrequent incirrhotic patients, many clinicians have tended to hesitateto introduce anti-platelet/coagulation therapy to theirpatients. Undoubtedly, this is due to the increased riskof hemorrhagic diathesis in cirrhotic patients. However,accumulating evidence has revealed the benefits ofanti-platelet/coagulation therapy for cirrhotic patients.In addition to the safety of the therapy carried outagainst cardiovascular diseases in cirrhotic patients,some clinical data have indicated its preventive effecton venous thrombosis. Moreover, the efficacy of antiplatelet/coagulation therapy against cirrhosis itself hasbeen demonstrated both clinically and experimentally.The conceptual basis for application of anti-platelet/coagulation therapy against cirrhosis was constructedthrough two pathologic studies on intrahepatic thrombosisin cirrhotic livers. It may be better to use thrombopoietinreceptoragonists, which have been tested as a treatmentfor cirrhosis-related thrombocytopenia, in combinationwith anti-platelet drugs to reduce the risk of venousthrombosis. During the last decade, the World Journalof Gastroenterology , a sister journal of World Journal ofHepatology , has been one of the main platforms of activediscussion of this theme.
